Customized Antibodies, CAR-T & Protein Services
mRNA-LNP Development
Completely validated mRNA-LNP platform—services include formulation & manufacturing
CAR-T/NK Development
CRO/CDMO services covering early discovery through to clinical trials
Antibody Engineering & Production
Flexible services focused on therapeutic applications
Fueling A New Era In Medicine
Since 2001, ProMab has built in-house expertise in the latest technologies to help our partners push the frontiers of medicine.
Today, we are the only provider that can offer CAR-T/NK development, mRNA-LNP development, and antibody engineering-highly promising technologies on their own and even more powerful when combined.
Turn tumors into cancer vaccines, manufacture antibodies in the body, build allogeneic cell therapies... imagine the possibilities and we'll help you bring them to life.
5,000+
monoclonal antibodies generated
3,000+
filed patents
500+
CAR-T project finished
4
Phase 2 clinical trials started
Services
CAR-T/CAR-NK Development
mRNA-Lipid Nanoparticle Development
Leverage our validated platform to advance your studies into the use of LNP-based delivery of mRNAs, including the development of vaccines, protein replacement therapies, engineered immune cells, or antibody-encoding mRNA therapies.
Cell-Based Assays
Protein Expression Services
Featured Publications
mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth Cancers (Basel). 2023 May; 15(10): 2860.
Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth Cancers (Basel). 2022 May 20;14(10):2518.
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma Cancers (Basel). 2021 Mar; 13(5): 981.
